Primary hyperaldosteronism and endothelial ischemia-reperfusion injury
- Conditions
- primary aldosteronismprimary hyperaldosteronism1001108210057166
- Registration Number
- NL-OMON38730
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 40
For patients with primary hyperaldosteronism:
-Age 18-75 years
-Confirmed primary hyperaldosteronism (aldosterone >0.28 nmol/L after salt loading)
-Serum potassium >= 3.5 mmol/L (with or without potassium supplementation)
-Written informed consent;For control patients with primary (essential) hypertension:
- Age 18-75 years
- Primary hypertension
- Baseline aldosterone <0.30 nmol/l and ARR<0.09.
- Serum potassium >= 3.5 mmol/L
- Written informed consent
-Smoking
-History of atherosclerotic disease (myocardial infarction (MI), stroke, or peripheral vascular disease)
-Not possible to change the antihypertensive medication into only diltiazem with or without hydralazine, or to temporarily stop statins according to the treating physician
-Severe renal dysfunction (MDRD < 30 ml/min)
-Second/third degree AV-block on electrocardiography
-Cardiac failure
-Diabetes mellitus
-Use of acetylsalicylic acid, NSAID*s, theophylline, and dipyridamole
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To study whether forearm IR impairs brachial artery FMD to a greater extent in<br /><br>patients with hypertension due to PHA than in patients with primary<br /><br>hypertension. </p><br>
- Secondary Outcome Measures
Name Time Method <p>To study whether CD73 activity on mononuclear cells is lower in patients with<br /><br>PHA, compared to patients with primary hypertension<br /><br>To study whether the circulating adenosine concentration in lower in patients<br /><br>with PHA</p><br>